NCT00394810View on ClinicalTrials.gov

Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Prostate Cancer
Interventions
DRUG

Panzem® NCD

suspension, 100 mg/mL, four times daily continuous dosing

Trial Locations (4)

21205

Johns Hopkins University School of Medicine, Baltimore

46202

Indiana University Cancer Center, Indianapolis

53792

University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison

02115

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY